000			02190nam a2200433Ia 4500
999			_c271707 _d271707
001			ocm55983220
003			OCoLC
005			20180706132118.0
007			he bmb024bbca
008			040721s2004 dcua bb f000 0 eng d
020			_a0160717140
020			_a9780160717147
040			_aPUCPR _beng _cFPS _dOCLCQ _dOCLCO _dOCLCQ _dOCLCA _dOCLCF _dGPO _dMvI
043			_an-us---
049			_aOnline
074			_a1019-B-01 (MF)
086	0		_aY 4.C 73/8:108-73
088			_aSerial no. 108-73 (United States. Congress. House. Committee on Energy and Commerce)
099			_aY 4.C 73/8:108-73
110	1		_aUnited States. _bCongress. _bHouse. _bCommittee on Energy and Commerce. _bSubcommittee on Health.
245	1	0	_aPrescription drug monitoring : _bstrategies to promote treatment and deter prescription drug use : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Eighth Congress, second session, March 4, 2004.
246	3	0	_aStrategies to promote treatment and deter prescription drug use
260			_aWashington : _bU.S. G.P.O. : _bFor sale by the Supt. of Docs., U.S. G.P.O., _c2004.
300			_aiii, 73 pages : _billustrations ; _c24 cm
336			_atext _btxt _2rdacontent
337			_amicroform _bh _2rdamedia
338			_amicrofiche _bhe _2rdacarrier
500			_a"Printed for the use of the Committee on Energy and Commerce."
500			_aShipping list no.: 2004-0382-M.
500			_a"Serial no. 108-73."
500			_aCRDP Program record.
504			_aIncludes bibliographical references.
533			_aMicrofiche. _bWashington : _cSupt. of Docs., U.S. G.P.O., _d2004. _e1 microfiche : negative.
650		0	_aMedication abuse _zUnited States _xPrevention.
650		0	_aMedication abuse _xLaw and legislation _zUnited States.
776	0	8	_iOnline version: _aUnited States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health. _tPrescription drug monitoring _w(OCoLC)680494127
776	0	8	_iPrint version: _aUnited States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health. _tPrescription drug monitoring _w(OCoLC)55688393
942			_2sudocs _c8